Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
about
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's DiseaseCurrent Research Therapeutic Strategies for Alzheimer's Disease TreatmentEarly Dementia ScreeningRecent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease DementiaDrug candidates in clinical trials for Alzheimer's disease.TANGO-Inspired Design of Anti-Amyloid Cyclic Peptides.Progresses in treating agitation: a major clinical challenge in Alzheimer's disease.Tau-directed approaches for the treatment of Alzheimer's disease: focus on leuco-methylthioninium.Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives.The need for new approaches in CNS drug discovery: Why drugs have failed, and what can be done to improve outcomes.Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies.Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer's disease patients.Finding chemopreventatives to reduce amyloid beta in yeast.GluN2B-NMDA receptors in Alzheimer's disease: beyond synapse loss and cell death.Cerebrospinal Fluid Proteins as Regulators of Beta-amyloid Aggregation and Toxicity.Tau aggregation inhibitors: the future of Alzheimer's pharmacotherapy?Association of Plasma β-Amyloid with Cognitive Performance and Decline in Chronic Kidney Disease.Tau-based therapeutics for Alzheimer's disease: active and passive immunotherapy.Transthyretin Mimetics as Anti-β-Amyloid Agents: A comparison of peptide and protein approaches.Chinese Herbal Medicine Xueshuantong Enhances Cerebral Blood Flow and Improves Neural Functions in Alzheimer's Disease Mice.
P2860
Q26739412-6CA132FB-3BC9-4771-AD86-1304E122A8F9Q26765530-DACFD49D-CB77-49EC-A535-6C66BA703A24Q26770171-3476C2A9-24C3-4716-8DC6-DF29268E07FDQ33556068-DD21AEF0-BE60-4624-8ADE-1BE452368C8BQ33562458-8D2F5CF6-EFF4-4D20-B797-B6CB387D6A9AQ33916749-79F5A361-3CA7-4478-BFDA-A25F4A168EBBQ36062167-73EB1A99-BA13-4186-846C-610CFD36210BQ38590192-3C16BA75-F3B1-4E0D-B440-D81C754429C7Q38715233-C940A7A3-4C56-4E25-A4FF-15A6E90B8555Q38719665-486880BD-4CC9-41A8-A6E6-F1D553A1A76FQ38775856-4C7B2C73-D260-471F-B872-8663A61EC75FQ38826744-BC3D5A69-CD32-480A-81E4-A9764860981CQ38966308-6EF86B05-48BB-479B-B1CE-66ED263C7181Q39613246-3F0EA97D-20D6-49A5-9AE6-AF2837636C08Q41855604-B0CC8E33-669F-48FA-8B6B-1329D52EFA77Q47356578-17A9E380-630B-45DA-B9C6-718CFE5FE124Q48239696-DEE2225D-21A7-4B3B-A6D5-183DD18E97D8Q48450061-B6E908DC-7DF5-403E-A2F1-21849FEAC95DQ50632272-EBDFCE8A-92C0-444C-A3E0-4B0EA0D30DF2Q51735672-5E15AE9B-C5C9-4B4A-8810-B899FFCCC8AAQ55259822-D95BCE6A-84CE-4994-9198-D120A51C148F
P2860
Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Amyloid-directed monoclonal an ...... sease: the point of no return?
@en
type
label
Amyloid-directed monoclonal an ...... sease: the point of no return?
@en
prefLabel
Amyloid-directed monoclonal an ...... sease: the point of no return?
@en
P2860
P1476
Amyloid-directed monoclonal an ...... sease: the point of no return?
@en
P2093
Bruno P Imbimbo
Vincenzo Solfrizzi
P2860
P304
P356
10.1517/14712598.2014.935332
P407
P577
2014-06-30T00:00:00Z